You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Lixte terminates license agreement with Taipei Medical University
AT&T To Use Wireless Subs To Create Buzz For HBO
Creating an Efficient Enterprise Wide Credit Risk Management System for a Leading Energy Company
Power and Gas M&A Symposium - 2019 Highlights
Financial Plumbing Prone To Clogging Amid Bank Liquidity Trap
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.